0001214659-23-016095.txt : 20231206 0001214659-23-016095.hdr.sgml : 20231206 20231206161518 ACCESSION NUMBER: 0001214659-23-016095 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231206 FILED AS OF DATE: 20231206 DATE AS OF CHANGE: 20231206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biodexa Pharmaceuticals Plc CENTRAL INDEX KEY: 0001643918 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37652 FILM NUMBER: 231469767 BUSINESS ADDRESS: STREET 1: 1 CASPIAN POINT STREET 2: CASPIAN WAY CITY: CARDIFF STATE: X0 ZIP: CF10 4DQ BUSINESS PHONE: 44 (0)1235 888300 MAIL ADDRESS: STREET 1: 1 CASPIAN POINT STREET 2: CASPIAN WAY CITY: CARDIFF STATE: X0 ZIP: CF10 4DQ FORMER COMPANY: FORMER CONFORMED NAME: Midatech Pharma Plc DATE OF NAME CHANGE: 20150602 6-K 1 j1262306k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of December 2023

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

The information included in this report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-267932) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXPLANATORY NOTE

As previously disclosed, pursuant to Section 5.4 of the Amended and Restated Deposit Agreement, dated as of February 8, 2021, by and among Biodexa Pharmaceuticals PLC (the “Company”), The Bank of New York Mellon, as depositary (“BONY”), and all holders and beneficial owners of the Company’s American depositary shares issued thereunder (the “BONY Deposit Agreement”), BONY provided written notice to the Company of BONY’s resignation, such resignation to take effect upon the appointment by the Company of a successor depositary and its acceptance of such appointment as provided in the BONY Deposit Agreement.

On December 5, 2023, the Company appointed JPMorgan Chase Bank, N.A. (“JPMorgan”) as successor depositary. The Company expects JPMorgan to commence serving as successor depositary on or about December 18, 2023. In conjunction with such change, a Second Amended and Restated Deposit Agreement (the “New Deposit Agreement”), between the Company and JPMorgan will take effect on such date and each existing American depositary receipt will be deemed amended and restated accordingly. The holders and beneficial owners of the Company’s American depositary receipts from time to time shall become parties to, and be bound by all of the terms and conditions of, the New Deposit Agreement. A copy of the form of New Deposit Agreement is filed as Exhibit (a) to the Registration Statement on Form F-6 (File No. 333-275909), filed with the Securities and Exchange Commission on December 6, 2023.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Biodexa Pharmaceuticals PLC

Date: December 6, 2023	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer and Chief Financial Officer